prikaz prve stranice dokumenta Učinkovitost i sigurnost bioloških DMARD i ciljanih sintetskih DMARD lijekova u bolesnika s upalnim reumatskim bolestima
  Download
PDF 867.31 KB
master's thesis
Učinkovitost i sigurnost bioloških DMARD i ciljanih sintetskih DMARD lijekova u bolesnika s upalnim reumatskim bolestima
2020. urn:nbn:hr:152:725465
Mileta, Antonio
Josip Juraj Strossmayer University of Osijek
Faculty of Medicine Osijek

Cite this document

Mileta, A. (2020). Učinkovitost i sigurnost bioloških DMARD i ciljanih sintetskih DMARD lijekova u bolesnika s upalnim reumatskim bolestima (Master's thesis). Osijek: Josip Juraj Strossmayer University of Osijek, Faculty of Medicine Osijek. Retrieved from https://urn.nsk.hr/urn:nbn:hr:152:725465

Mileta, Antonio. "Učinkovitost i sigurnost bioloških DMARD i ciljanih sintetskih DMARD lijekova u bolesnika s upalnim reumatskim bolestima." Master's thesis, Josip Juraj Strossmayer University of Osijek, Faculty of Medicine Osijek, 2020. https://urn.nsk.hr/urn:nbn:hr:152:725465

Mileta, Antonio. "Učinkovitost i sigurnost bioloških DMARD i ciljanih sintetskih DMARD lijekova u bolesnika s upalnim reumatskim bolestima." Master's thesis, Josip Juraj Strossmayer University of Osijek, Faculty of Medicine Osijek, 2020. https://urn.nsk.hr/urn:nbn:hr:152:725465

Mileta, A. (2020). 'Učinkovitost i sigurnost bioloških DMARD i ciljanih sintetskih DMARD lijekova u bolesnika s upalnim reumatskim bolestima', Master's thesis, Josip Juraj Strossmayer University of Osijek, Faculty of Medicine Osijek, accessed 22 November 2024, https://urn.nsk.hr/urn:nbn:hr:152:725465

Mileta A. Učinkovitost i sigurnost bioloških DMARD i ciljanih sintetskih DMARD lijekova u bolesnika s upalnim reumatskim bolestima [Master's thesis]. Osijek: Josip Juraj Strossmayer University of Osijek, Faculty of Medicine Osijek; 2020 [cited 2024 November 22] Available at: https://urn.nsk.hr/urn:nbn:hr:152:725465

A. Mileta, "Učinkovitost i sigurnost bioloških DMARD i ciljanih sintetskih DMARD lijekova u bolesnika s upalnim reumatskim bolestima", Master's thesis, Josip Juraj Strossmayer University of Osijek, Faculty of Medicine Osijek, Osijek, 2020. Available at: https://urn.nsk.hr/urn:nbn:hr:152:725465

Please login to the repository to save this object to your list.
Metadata
TitleUčinkovitost i sigurnost bioloških DMARD i ciljanih sintetskih DMARD lijekova u bolesnika s upalnim reumatskim bolestima
Title (english)Efficacy and safety of biologic DMARDs and targeted synthetic DMARDs in patients with inflammatory rheumatic diseases
AuthorAntonio Mileta
MentorJasminka Milas-Ahić (mentor)
Committee memberVlatka Periša (predsjednik povjerenstva)
Committee memberJerko Barbić (član povjerenstva)
Committee memberJasminka Milas-Ahić (član povjerenstva)
GranterJosip Juraj Strossmayer University of Osijek
Faculty of Medicine Osijek
Osijek
Defense date and country2020-09-21, Croatia
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Abstract
Ciljevi istraživanja: Ispitati učinkovitost i sigurnost biološke terapije, ispitati učinkovitost i sigurnost ciljane sintetske terapije te usporediti učinkovitost i sigurnost biološke i ciljane sintetske terapije Nacrt studije: presječna studija Ispitanici i metode: Ispitanici su 248 pacijenata s dijagnozom reumatoidnog artritisa, ankilozantnog spondilitisa ili psorijatičnog artritisa obrađeni na Zavodu za reumatologiju, kliničku imunologiju i alergologiju KBC-a Osijek liječenih biološkom ili ciljano sintetskom terapijom. Podatci o ispitanicima prikupljeni su tijekom srpnja i kolovoza 2020. godine, a preuzeti podatci su dob, spol, dob postavljanja dijagnoze, razine CRP-a i SE-a, vrijednosti indeksa DAS28, HAQ, BASDAI, BASFI i ASDAS, pojavnost malignih oboljenja, kardiovaskularnih i cerebrovaskularnih događaja, infekcija i tuberkuloze, vrste bioloških lijekova, linija liječenja te razlog prekida ili promjene terapije. Rezultati: JAK-inhibitori i inhibitori IL-6 značajno su više snizili vrijednost DAS28 nakon 3 mjeseca terapije u odnosu na inhibitore CD20 i inhibitore TNF-α. Inhibitori TNF-α statistički značajno više snižavaju vrijednosti BASDAI, BASFI i ASDAS nakon 3 mjeseca te ASDAS nakon 12 mjeseci u usporedbi s inhibitorima IL-17. Nije uočena statistički značajna razlika u sigurnosnim profilima između terapija. Statistički značajno najzastupljenija je prva linija liječenja. Zaključak: Biološka i ciljana sintetska terapija učinkovite su u liječenju upalnih reumatskih bolesti te imaju zadovoljavajući sigurnosni profil. Uspoređivanjem njihove učinkovitosti i sigurnosti nisu pronađene značajne razlike.
Abstract (english)
Objectives: The aim of this study was to examine efficacy and safety of biologic DMARDs and targeted synthetic DMARDs and to compare efficacy and safety of biologic DMARDs and targeted synthetic DMARDs Study design: cross-sectional study Participants and methods: The study included 248 patients diagnosed with rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis treated at the Department of Rheumatology, Clinical Immunology and Alergology of University Hospital Center Osijek. Data were collected during July and August 2020 from patients’ medical history. The data included age, sex, age of diagnosis, CRP and ESR levels, DAS28, HAQ, BASDAI, BASFI and ASDAS values, incidence of malignancy, cardiovascular and cerebrovascular disorder, infections and tuberculosis, type of biologic therapy, line of treatment and reason of terminating or switching therapy. Results: JAK-inhibitors and IL-6 inhibitors lowered value of DAS28 after 3 months of therapy significantly more compared to CD20 inhibitors and TNF-α inhibitors. TNF-α inhibitors lowered value of BASDAI, BASFI and ASDAS after 3 months of therapy and value of ASDAS after 12 months of therapy statistically significantly more than IL-17 inhibitors. Statistically significant difference of safety profiles between therapies was not observed. First line of the treatment was significantly most represented. Conclusion: Biologic and targeted synthetic therapy are effective treatments of inflammatory rheumatic diseases and they have good safety profile. In comparing their efficacy and safety, no significant differences we found.
Keywords
Keywords (english)
Languagecroatian
URN:NBNurn:nbn:hr:152:725465
Study programmeTitle: University Graduate Studies
Study programme type: university
Study level: integrated undergraduate and graduate
Academic / professional title: doktor/doktorica medicine (doktor/doktorica medicine)
Type of resourceText
File originBorn digital
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2022-10-12 11:09:31